Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
12 Aug, 20:00
NYSE NYSE
$
260. 86
+1.06
+0.408%
After Hours
$
261. 80
+0.94 +0.3603%
620.77B Market Cap
29.06 P/E Ratio
0.69% Div Yield
3.26M Volume
9.91 Eps
$ 259.8
Previous Close
Add Transaction
Day Range
255.25 261.41
Year Range
172.7 274.9
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Johnson & Johnson: Rich History Of Excellence Poised To Endure

Johnson & Johnson: Rich History Of Excellence Poised To Endure

Johnson & Johnson offers a compelling balance of growth, innovation, and shareholder returns. JNJ's robust financials, including a fortress-like balance sheet and consistent dividends, support its ability to drive growth and innovation. The company is well-diversified across thriving healthcare segments, with promising FDA approvals and strategic M&A initiatives enhancing its market position.

Seekingalpha | 1 year ago
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?

J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?

Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.

Zacks | 1 year ago
J&J resumes US rollout of Varipulse heart device after investigation

J&J resumes US rollout of Varipulse heart device after investigation

Johnson & Johnson said on Friday it has resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended.

Reuters | 1 year ago
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results

Johnson & Johnson halts late-stage E.coli vaccine trial after poor results

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.

Nypost | 1 year ago
J&J to discontinue E.coli vaccine candidate study

J&J to discontinue E.coli vaccine candidate study

Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi.

Reuters | 1 year ago
What's a Fair Price to Buy Johnson & Johnson Stock?

What's a Fair Price to Buy Johnson & Johnson Stock?

Johnson & Johnson (JNJ 1.23%) is forecast to increase its free cash flow significantly over the next five years and beyond.

Fool | 1 year ago
Are You Looking for a High-Growth Dividend Stock?

Are You Looking for a High-Growth Dividend Stock?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Zacks | 1 year ago
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
DCLA's Sarat Sethi on his top stock picks: JNJ, WDAY, TMO

DCLA's Sarat Sethi on his top stock picks: JNJ, WDAY, TMO

Sarat Sethi, DCLA managing partner, joins 'Squawk Box' to discuss the latest market trends, his top stock picks, and more.

Youtube | 1 year ago
You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth

You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth

A buy-and-hold strategy is ideal for investors seeking durable companies with strong dividends and attractive valuations, avoiding tax inefficiencies from frequent trading. UPS offers a 5.7% dividend yield, trading at a forward P/E of 13.5, with potential for profitability expansion despite near-term Amazon volume reductions. Johnson & Johnson, with a 3.3% dividend yield and a forward P/E of 14.4, carries a robust pipeline and 62 years of consecutive dividend growth.

Seekingalpha | 1 year ago
Is Johnson & Johnson Stock a Buy?

Is Johnson & Johnson Stock a Buy?

Johnson & Johnson (JNJ -0.47%) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy.

Fool | 1 year ago
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?

Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?

Johnson & Johnson (JNJ -0.47%) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, is growth.

Fool | 1 year ago
Loading...
Load More